145 related articles for article (PubMed ID: 21749867)
21. Hypoxia-inducible erythropoietin signaling in squamous dysplasia and squamous cell carcinoma of the uterine cervix and its potential role in cervical carcinogenesis and tumor progression.
Acs G; Zhang PJ; McGrath CM; Acs P; McBroom J; Mohyeldin A; Liu S; Lu H; Verma A
Am J Pathol; 2003 Jun; 162(6):1789-806. PubMed ID: 12759237
[TBL] [Abstract][Full Text] [Related]
22. Erythropoietin augments survival of glioma cells after radiation and temozolomide.
Hassouna I; Sperling S; Kim E; Schulz-Schaeffer W; Rave-Fränk M; Hasselblatt M; Jelkmann W; Giese A; Ehrenreich H
Int J Radiat Oncol Biol Phys; 2008 Nov; 72(3):927-34. PubMed ID: 19014782
[TBL] [Abstract][Full Text] [Related]
23. Expression pattern of erythropoietin and erythropoietin receptor in experimental model of retinal detachment.
Xie Z; Wu X; Qiu Q; Gong Y; Song Y; Gu Q; Li C
Curr Eye Res; 2007 Sep; 32(9):757-64. PubMed ID: 17882708
[TBL] [Abstract][Full Text] [Related]
24. De novo erythropoietin receptor (EPO-R) expression in human neoplastic glial cells decreases with grade of malignancy but is favourably associated with patient survival.
Mittelbronn M; Capper D; Bunz B; Dietz K; Goeppert B; Ajaaj R; Tabatabai G; Stubenvoll F; Schlaszus H; Merseburger AS; Becker R; Freudenstein D; Wick W; Weller M; Meyermann R; Simon P
Neuropathol Appl Neurobiol; 2007 Jun; 33(3):299-307. PubMed ID: 17493011
[TBL] [Abstract][Full Text] [Related]
25. Erythropoietin is a paracrine mediator of ischemic tolerance in the brain: evidence from an in vitro model.
Ruscher K; Freyer D; Karsch M; Isaev N; Megow D; Sawitzki B; Priller J; Dirnagl U; Meisel A
J Neurosci; 2002 Dec; 22(23):10291-301. PubMed ID: 12451129
[TBL] [Abstract][Full Text] [Related]
26. Expression of erythropoietin and angiogenic growth factors following inner ear injury of newborn rats.
Gross J; Moller R; Amarjargal N; Machulik A; Fuchs J; Ungethüm U; Kuban RJ; Henke W; Haupt H; Mazurek B
Prague Med Rep; 2009; 110(4):310-31. PubMed ID: 20059883
[TBL] [Abstract][Full Text] [Related]
27. Post-secretion neutralization of transgene-derived effect: soluble erythropoietin receptor/IgG1Fc expressed in liver neutralizes erythropoietin produced in muscle.
Maruyama H; Higuchi M; Higuchi N; Kameda S; Saito M; Sugawa M; Matsuzaki J; Neichi T; Yokoyama S; Miyazaki Y; Miyazaki J; Gejyo F
J Gene Med; 2004 Feb; 6(2):228-37. PubMed ID: 14978776
[TBL] [Abstract][Full Text] [Related]
28. Erythropoietin-induced erythroid differentiation of the human erythroleukemia cell line TF-1 correlates with impaired STAT5 activation.
Chrétien S; Varlet P; Verdier F; Gobert S; Cartron JP; Gisselbrecht S; Mayeux P; Lacombe C
EMBO J; 1996 Aug; 15(16):4174-81. PubMed ID: 8861946
[TBL] [Abstract][Full Text] [Related]
29. Lack of functional erythropoietin receptors of cancer cell lines.
Laugsch M; Metzen E; Svensson T; Depping R; Jelkmann W
Int J Cancer; 2008 Mar; 122(5):1005-11. PubMed ID: 17990315
[TBL] [Abstract][Full Text] [Related]
30. Lineage-restricted recruitment of immature hematopoietic progenitor cells in response to Epo after normal hematopoietic cell transfection with EpoR.
McArthur GA; Longmore GD; Klingler K; Johnson GR
Exp Hematol; 1995 Jul; 23(7):645-54. PubMed ID: 7601257
[TBL] [Abstract][Full Text] [Related]
31. Expression patterns of erythropoietin and its receptor in the developing spinal cord and dorsal root ganglia.
Knabe W; Sirén AL; Ehrenreich H; Kuhn HJ
Anat Embryol (Berl); 2005 Oct; 210(3):209-19. PubMed ID: 16151855
[TBL] [Abstract][Full Text] [Related]
32. The role of erythropoietin in regulating angiogenesis.
Kertesz N; Wu J; Chen TH; Sucov HM; Wu H
Dev Biol; 2004 Dec; 276(1):101-10. PubMed ID: 15531367
[TBL] [Abstract][Full Text] [Related]
33. Inhibition of platelet-derived growth factor-mediated signal transduction and tumor growth by N-[4-(trifluoromethyl)-phenyl]5-methylisoxazole-4-carboxamide.
Shawver LK; Schwartz DP; Mann E; Chen H; Tsai J; Chu L; Taylorson L; Longhi M; Meredith S; Germain L; Jacobs JS; Tang C; Ullrich A; Berens ME; Hersh E; McMahon G; Hirth KP; Powell TJ
Clin Cancer Res; 1997 Jul; 3(7):1167-77. PubMed ID: 9815796
[TBL] [Abstract][Full Text] [Related]
34. Expression of erythropoietin and its receptor in neuroblastomas.
Sartelet H; Fabre M; Castaing M; Bosq J; Racu I; Lagonotte E; Scott V; Lecluse Y; Barette S; Michiels S; Vassal G
Cancer; 2007 Sep; 110(5):1096-106. PubMed ID: 17647284
[TBL] [Abstract][Full Text] [Related]
35. Erythropoietin receptor contributes to melanoma cell survival in vivo.
Kumar SM; Zhang G; Bastian BC; Arcasoy MO; Karande P; Pushparajan A; Acs G; Xu X
Oncogene; 2012 Mar; 31(13):1649-60. PubMed ID: 21860424
[TBL] [Abstract][Full Text] [Related]
36. RNA interference targeting NRP-1 inhibits human glioma cell proliferation and enhances cell apoptosis.
Li X; Tang T; Lu X; Zhou H; Huang Y
Mol Med Rep; 2011; 4(6):1261-6. PubMed ID: 21842123
[TBL] [Abstract][Full Text] [Related]
37. Lycii cortex radicis extract inhibits glioma tumor growth in vitro and in vivo through downregulation of the Akt/ERK pathway.
Jeong JC; Kim SJ; Kim YK; Kwon CH; Kim KH
Oncol Rep; 2012 May; 27(5):1467-74. PubMed ID: 22266745
[TBL] [Abstract][Full Text] [Related]
38. Erythropoietin-receptor gene regulation in neuronal cells.
Wallach I; Zhang J; Hartmann A; van Landeghem FK; Ivanova A; Klar M; Dame C
Pediatr Res; 2009 Jun; 65(6):619-24. PubMed ID: 19218878
[TBL] [Abstract][Full Text] [Related]
39. Erythropoietin blockade inhibits the induction of tumor angiogenesis and progression.
Hardee ME; Cao Y; Fu P; Jiang X; Zhao Y; Rabbani ZN; Vujaskovic Z; Dewhirst MW; Arcasoy MO
PLoS One; 2007 Jun; 2(6):e549. PubMed ID: 17579721
[TBL] [Abstract][Full Text] [Related]
40. RNA interference-mediated inhibition of erythropoietin receptor expression suppresses tumor growth and invasiveness in A2780 human ovarian carcinoma cells.
Paragh G; Kumar SM; Rakosy Z; Choi SC; Xu X; Acs G
Am J Pathol; 2009 Apr; 174(4):1504-14. PubMed ID: 19264915
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
